Pharmacognosy intro
Commiphora myrrh (Nees) Engl., family Burseraceae, produces an oleo-gum resin composed of 30-60% water-soluble gum (acidic polysaccharides), 25-40% alcohol-soluble resin (commiphoric and commiphorinic acids), and 3-8% volatile oil rich in furanosesquiterpenes. Known as myrrh, mo yao (Chinese), bola (Ayurvedic), and murr (Arabic), the resin is naturally exuded or harvested from bark fissures on trees native to northeastern Africa and the Arabian Peninsula. The volatile oil fraction contains a chemically distinctive class of furanosesquiterpenes rarely found elsewhere in the plant kingdom. Furanoeudesma-1,3-diene interacts directly with opioid receptors, contributing to analgesic activity through a unique non-alkaloid pain pathway. Curzerene, a related furanosesquiterpene, serves as an analgesic synergist and converts to furanodiene upon heating. 2-Methoxyfuranodiene and 2-acetoxyfuranodiene provide additional anti-inflammatory and antimicrobial activity. Lindestrene, a sesquiterpene smooth muscle relaxant, contributes antispasmodic effects. Beta-elemene has documented anticancer activity across multiple tumor cell lines. This furanosesquiterpene-dominant chemistry distinguishes myrrh from virtually all other resinous aromatics. Human clinical evidence supports analgesic and anti-inflammatory applications. Germano et al. (2017, BioMed Research International) conducted a pilot study demonstrating analgesic and anti-inflammatory effects of myrrh extract in oral health applications, identifying furanodiene compounds as the primary active agents via opioid pathway interaction. A randomized controlled trial by Alkanat et al. (2023), referenced in Aly et al. (2025, Phytotherapy Research), found that aromatherapy massage with frankincense and myrrh produced statistically significant reductions in VAS pain scores, Aberdeen Low Back Pain Scale, and Roland-Morris Disability Scale compared to both control and massage-only groups (p < 0.001 for all metrics). Hu et al. (2017, Neural Plasticity) demonstrated synergistic anti-inflammatory effects of the frankincense-myrrh combination through TRPV1 modulation and MAPK pathway regulation, exceeding either resin alone. Toxicity is moderate: LD50 of 1.65 g/kg (oral, rat), classified as slightly toxic. Myrrh is fetotoxic with documented uterine stimulant activity; it must be avoided during pregnancy. Contact dermatitis has been reported in sensitive individuals. The resin may interact with anticoagulants (consistent with its blood-moving classification in TCM) and may potentiate hypoglycemic medications.